Site capabilities for drug trials

Conducting a clinical trial of a medicinal product among children requires more than the presence of experienced clinical staff and appropriate patient populations. Additional operational capabilities must be assessed and confirmed before a site can be activated: the availability of a pharmacy that can safely receive, store, prepare and dispense an investigational medicinal product formulated for children; and the availability of laboratory services capable of processing the biological samples required by the protocol, especially for pharmacokinetic studies and blood collection for monitoring toxicity side-effects

Pharmacy requirements for paediatric trials

In any trial of a medicinal product, the site pharmacy (or a designated pharmacy function) is responsible for the receipt, storage, preparation, dispensing and accountability of the investigational medicinal product. In paediatric drug trials, the pharmacy role is substantially more complex than in most adult trials, for several reasons. Many paediatric investigational medicinal products are presented as liquids, oral suspensions or dispersible tablets rather than standard solid dosage forms and may require reconstitution, dilution or other preparation steps before administration. Weight-based dosing (see Module 1) – in which the dose is calculated based on the child’s current weight at each visit – requires accurate weighing of the child and dose calculation at or before each dispensing event. Paediatric investigational medicinal products may also have specific and narrow storage requirements, including temperature-controlled storage, protection from light or short post-reconstitution shelf lives, all of which must be rigorously managed.

The site pharmacy must also maintain full drug accountability records for the investigational medicinal product, documenting receipt, storage conditions, dispensing (including the dose dispensed, the child’s weight at the time of dispensing and the person who dispensed), returns and destruction. Blinding presents additional challenges in paediatric trials: when age-appropriate formulations have distinctive tastes, appearances, or odours, maintaining effective blinding of participants, caregivers and clinical staff may require specific matching of placebo formulations or using blinded dispensing procedures

The minimum pharmacy requirements for a paediatric drug trial include:

  • a designated, appropriately trained pharmacist or pharmacy technician responsible for investigational medicinal product management;
  • a secure, temperature-monitored storage area meeting the investigational medicinal product’s specified storage conditions;
  • calibrated weighing scales suitable for paediatric weights; documented standard operating procedures for receipt, storage, preparation, dispensing and accountability of the investigational medicinal product; and
  • a system for monitoring and recording storage conditions (including continuous temperature logging for refrigerated products).

When a site does not have an on-site pharmacy meeting these requirements, a central pharmacy or satellite dispensing arrangement may be possible but must be explicitly documented and approved by the ethics committee and regulatory authority. In low- and middle-income country settings with limited pharmacy infrastructure, the sponsor and site must work together to implement pragmatic solutions – such as pre-prepared unit-dose syringes or sachets dispatched from a central facility – that maintain quality and accountability without requiring local pharmacy preparation capability that the site cannot sustain.

Laboratory requirements for pharmacokinetic sampling and safety testing

Pharmacokinetic studies are a core component of many paediatric drug trials, especially in early-phase studies and require both a clinical site capability (collecting and initially processing samples) and a bioanalytical capability (measuring drug concentrations in biological matrices). These are usually separate functions: clinical sites collect and initially process samples according to the sponsor’s laboratory manual and then ship them to a central or specialist bioanalytical laboratory for analysis. Understanding what each party is responsible for and what the site must be able to do independently is essential for site qualification.

At the site level, the key laboratory requirements for pharmacokinetic sampling depend on the sample matrix specified in the protocol. For conventional plasma pharmacokinetic studies, the site must be able to collect venous or capillary blood into the correct tube type at the specified time points, process samples promptly, transfer the plasma into labelled aliquot tubes and store samples at the required temperature pending shipment. This requires access to:

  • a centrifuge with appropriate speed and temperature settings;
  • a −20°C or −70°C freezer with temperature monitoring;
  • a reliable cold chain for sample shipment (usually dry ice);
  • appropriate tubes, pipettes and labelling materials supplied by the sponsor; and
  • trained staff

Dried blood spot sampling offers a significant practical advantage in paediatric and low- and middle-income country settings by eliminating the need for centrifugation, cold-chain shipment and the large blood volumes required for conventional plasma pharmacokinetics. In dried blood spot sampling, a small volume of capillary blood collected by finger or heel prick is spotted onto filter paper, dried at ambient temperature and shipped to the bioanalytical laboratory at room temperature. Dried blood spot substantially simplifies site-level requirements and reduces participant burden but must be conducted by well-trained staff.

The sponsor is responsible for providing the site with a detailed laboratory manual that specifies all aspects of sample collection, processing, storage and shipping. Staff training on the laboratory manual should be conducted before the first participant is enrolled, and competence should be documented. A pre-study feasibility exercise, in which staff practise the full sampling and processing workflow before conducting it with children, is recommended, especially for sites without previous experience of pharmacokinetic sampling in paediatric populations. The LENA project feasibility study provides a validated model for this type of pre-study assessment across multiple paediatric clinical sites. The described sampling techniques and laboratory workflows also apply to specimen collection for safety testing and toxicity assessment.

Key resources